期刊文献+

阿尔茨海默病患者日常生活能力下降影响因素分析

To analysethe factors affecting the decline in the level of activities of daily living in patients with Alzheimer’s disease
下载PDF
导出
摘要 目的:对影响轻中度阿尔茨海默病患者日常生活能力下降的因素进行分析。方法:对64例轻中度阿尔茨海默病患者进行16周的随访调查,调查开始及16周后均行简易智能状态量表(MMSE)、蒙特利尔认知评估量表(MoCA)、日常生活能力量表(ADCS-ADL)、阿尔茨海默病评价量表-认知分量表(ADAS-cog)等评估。结果:未用药组入组前MMSE评分、MoCA评分、ADCS-ADL评分及ADAS-cog评分分别为20.50±3.53分、18.67±7.01分、17.50±11.73分及45.17±4.28分,16周观察期后分别为18.25±6.23分、17.92±6.96分、18.67±12.23分及43.67±7.72分,均有恶化趋势,但前后差异没有统计学意义;单用药组入组前MMSE评分、MoCA评分、ADCS-ADL评分及ADAS-cog评分分别为19.50±4.50分、17.30±5.47分、16.13±9.24分及46.50±5.59分,16周观察期后分别为22.73±4.88分、17.83±6.34分、14.50±8.20分及48.58±5.63分,在MMSE评分、ADAS-cog评分和ADCS-ADL评分较前有改善,差异有统计学意义;联用药组入组前MMSE评分、MoCA评分、ADCS-ADL评分及ADAS-cog评分分别为18.75±2.63分、18.58±5.02分、19.08±18.00分及42.58±6.59分,16周观察期后分别为24.83±6.22分、19.67±4.10分、16.42±15.54分及48.00±5.83分,16周后的评分较入组前的评分均有改善,差异有统计学意义。多元线性回归分析显示,受教育程度、基础ADCS-ADL评分、抗痴呆治疗方案及照料对于ADCS-ADL评分变化有影响,P<0.05。结论:尽早联合应用抗痴呆类药物及加强照料具有改善AD患者日常生活能力的作用,而受教育程度也在其中起到积极的作用。 Objective To analyze the factors influencing the decline of Ability of daily life in patients with mild to moderate Alzheimer’s disease.Methods 64 patients with mild to moderate Alzheimer’s disease were followed up for 16 weeks.MMSE,MoCA,ADCS-ADL and ADAS-cog were assessed at the beginning and after 16 weeks.Results In the group without anti dementia drugs,MMSE score,MoCA score,ADCS-ADL score and ADAS-cog score were 20.50±3.53,18.67±7.01,17.50±11.73 and 45.17±4.28,respectively.After 16 weeks of observation,they were 18.25±6.23,17.92±6.96,18.67±12.23 and 43.67±7.72,respectively,all with deterioration trend,but there was no statistical significance before and after the observation;In thegroup treated with single anti dementia drug,the MMSE score,MoCA score,ADCS-ADL score and ADAS-cog score were 19.50±4.50,17.30±5.47,16.13±9.24 and 46.50±5.59,respectively,and they were 22.73±4.88,17.83±6.34,14.50±8.20 and 48.58±5.63 after 16 weeks of observation.There were significant differences in MMSE score,ADAS-cog score and ADCS-ADL score;The MMSE score,MoCA score,ADCS-ADL score and ADAS-cog score were 18.75±2.63,18.58±5.02,19.08±18.00 and 42.58±6.59 respectively in the combination group,and they were 24.83±6.22,19.67±4.10,16.42±15.54 and 48.00±5.83 respectively after 16 weeks of observation,the score was improved and the difference was statistically significant.Multiple linear regression analysis showed that education level,basic ADCS-ADL score,anti dementia treatment plan and care had influence on ADCS-ADL score(P<0.05).Conclusions Early combination of anti dementia drugs and intensive care can improve the ability of daily life of AD patients,and education also plays a positive role.
作者 肖天祎 王洪权 李延峰 Xiao Tian-yi;Wang Hong-quan;Li Yan-feng(Department of Neurology,Aerospace Central Hospital,Peking University Aerospace Clinical College;Department of Neurology,Peking Union Medical College Hospital,CAMS&PUMC)
出处 《阿尔茨海默病及相关病杂志》 2020年第1期37-41,共5页 Chinese Journal of Alzheimer's Disease and Related Disorders
基金 国家自然科学基金项目(61971011) 北京自然科学基金项目(Z170003)。
关键词 阿尔茨海默病 多元线性回归分析 Alzheimer’s disease multiple linear regression analysis
  • 相关文献

参考文献7

二级参考文献33

  • 1陈霞,张振馨,王新德,姚景莉,陈生弟,钱采韻,肖世富,舒良,汤洪川.美金刚在阿尔茨海默病患者中的疗效与耐受性多中心研究[J].中华神经科杂志,2007,40(6):364-368. 被引量:18
  • 2Parsons CG,Danysz W,Quack G.Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data.Neuropharmacology,1999,38:735-767.
  • 3American psychiatric assosition.Diagnostic and statistical manual of mental disorders.4th ed.Washington:American Psychiatric Press,1994.147-154.
  • 4McKhann G,Drachman D,Folstein M,et al.Clinical diagnosis of Alzheimer's disease:report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.Neurology,1984,34:939-944.
  • 5Blessed G,Tomlinson BE,Roth M.Blessed-Roth Dementia Scale (DS).Psychopharmacol Bull,1988,24:705-708.
  • 6Cacabelos R,Takeda M,Winblad B.The glutamatergic system and neurodegeneration in dementia:preventive strategies in Alzheimer's disease.Int J Geriatr Psychiatry,1999,14:3-47.
  • 7Tariot PN,Farlow MR,Grossberg GT,et al.Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil:a randomized controlled trial.JAMA,2004,291:317-324.
  • 8Reisberg B,Doody R,Stoffler A,et al.Memantine in moderate-to-severe Alzheimer's disease.N Engl J Med,2003,348:1333-1341.
  • 9Winblad B,Poritis N.Memantine in severe dementia:results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).Int J Geriatr Psychiatry,1999,14:135-146.
  • 10Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial f-J]. Am J Geriatr Psychi, 2006, 14: 704-715.

共引文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部